Active Biotech Q2 FY26 operating loss narrows to SEK 10.2 million

• Active Biotech posted a Q2 operating loss of SEK 10.2 million, narrowing from SEK 11.3 million a year earlier.
• Loss after tax improved to SEK 10.1 million from SEK 11.2 million, while EPS strengthened to SEK -0.38 from SEK -0.91.
• Cash and cash equivalents totaled SEK 43.9 million at June 30, up from SEK 16.8 million a year earlier.
• Net sales remained at no revenue in the quarter.
• Key updates included renewed European clearance to resume HOVON 172 MF enrolment, with the first patient dosed July 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.